INSIGHTS INTO THE WORLD OF SEEING

Nerve Regenerative Agents for the Treatment of Eye Disorders

Preclinical up through Phase 2 dry-eye disease clinical trials have shown that NRO-1 enhanced neurite elongation of Retinal Ganglion Cells (RGCs) significantly.   

NRO-1 PROGRAMS

PRECLINICAL

PHASE 1

PHASE 2

BACK TO TOP